Bortezomib (Velcade)

Size: px
Start display at page:

Download "Bortezomib (Velcade)"

Transcription

1 Bortezomib (Velcade) Policy Number: Original Effective Date: MM /09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription Drugs Place(s) of Service: Office; Outpatient I. Description Bortezomib (Velcade) is an antineoplastic agent known as a proteasome inhibitor. Proteasomes are enzymes found in cells and play an important role in regulating cell function and growth. Bortezomib blocks the activity of proteasomes. By blocking proteasomes, bortezomib disrupts processes related to the growth and survival of cancer cells. Bortezomib is an injectable and is FDA approved for the treatment of patients with multiple myeloma or mantle cell lymphoma. II. Criteria/Guidelines A. Bortezomib is covered (subject to Limitations and Administrative Guidelines) when recommended by a hematologist/oncologist for the following indications: 1. Multiple Myeloma a. Primary chemotherapy for solitary plasmacytoma that has progressed to active (symptomatic) myeloma or smoldering myeloma (asymptomatic) that has progressed to active (symptomatic) myeloma (See Appendix): i. In combination with dexamethasone with or without cyclophosphamide, doxorubicin, lenalidomide, or thalidomide for transplant candidates (all preferred regimens) ii. In combination with dexamethasone or in MPB (melphalan, prednisone, and bortezomib) regimen for nontransplant candidates (all preferred regimens) b. Maintenance therapy as a single agent: i. For active (symptomatic) myeloma responding to primary myeloma therapy ii. For stable or responsive disease following stem cell transplant iii. With second tandem transplant for stable or responsive disease following autologous stem cell transplant c. Therapy on or off clinical trials for disease relapse after 6 months following primary chemotherapy with the same regimen:

2 Bortezomib (Velcade) 2 i. In combination with dexamethasone with or without cyclophosphamide, doxorubicin, lenalidomide, or thalidomide for transplant candidates ii. In combination with dexamethasone or in MPB (melphalan, prednisone, and bortezomib) regimen for nontransplant candidates d. Therapy for previously treated myeloma on or off clinical trials for disease relapse or for progressive or refractory disease: i. As a single agent (preferred) ii. In combination with dexamethasone with or without lenalidomide, cyclophosphamide, or thalidomide (all preferred regimens) iii. In combination with liposomal doxorubicin (preferred) iv. In VTD-PACE (bortezomib, dexamethasone, thalidomide, cisiplatin, doxorubicin, cyclophosphamide, and etoposide) regimen (preferred) v. In combination with vorinostat 2. Multiple Myeloma associated with systemic light-chain amyloidosis when used in primary treatment as a single agent or in combination with dexamethasone with or without melphalan or with or without cyclophosphamide. 3. Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma when used as a single agent, in combination with dexamethasone, or in combination with rituximab with or without dexamethasone as: a. Primary therapy b. Therapy for previously treated disease that does not respond to primary therapy or for progressive or relapsed disease. 4. Non-Hodgkins Lymphoma adult T-cell leukemia/lymphoma when used in therapy for nonresponders to first-line therapy for acute disease or lymphoma in noncandidates for transplant. 5. Non-Hodgkins Lymphoma Mantle Cell Lymphoma when used as: a. Less aggressive induction therapy with VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone) regimen b. Second-line therapy with or without rituximab for relapsed, refractory, or progressive disease 6. Non-Hodgkins Lymphoma Peripheral T-Cell Lymphoma when used as second-line therapy for relapsed or refractory angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma not otherwise specified, anaplastic large cell lymphoma, or enteropathy-associated T-cell lymphoma in noncandidates for transplant. 7. Non-Hodgkins Lymphoma Primary Cutaneous CD30+ T-Cell Lymphroproliferative Disorders when used as single-agent therapy for relapsed or refractory: a. Primary cutaneous anaplastic large cell lymphoma (ALCL) with multifocal lesions b. Cutaneous ALCL with regional nodes (excludes systemic ALCL) B. For all indications, HMSA follows NCCN level 1 or 2A and/or DrugDex level I or IIa recommendations. C. Continuation of therapy for covered indications is covered (subject to Limitations and Administrative Guidelines) when initial therapy has been approved and the patient shows no progression of disease while on bortezomib.

3 Bortezomib (Velcade) 3 *Note: Refractory is defined as no longer responding to therapy. Relapsed is defined as the reappearance of disease in the region of prior disease (recurrence) and/or in new regions (extension) after initial therapy and attainment of complete response III. Limitations A. Bortezomib is not covered as first-line therapy for patients with peripheral T-cell lymphoma or non-hodgkins lymphoma. B. Bortezomib is not covered for a patient who has had progression of disease while on bortezomib. C. These criteria will continue to apply when bortezomib becomes available in generic form. IV. Administrative Guidelines A. Precertification is required for the initial six months of treatment. To precertify, please complete HMSA's Drug Review Request and mail or fax the form as indicated with the following documentation: 1. Clinical notes including previous treatments, if applicable. 2. Current oncology notes 3. Pathology reports 4. Pertinent laboratory reports that will be used to monitor patient s response to therapy (e.g., immunoglobulins, beta 2 microglobulin, free light chains). 5. Imaging studies, if applicable. B. Precertification is required for continuation of therapy for up to an additional six months. The following documentation from the medical record must be submitted: 1. Clinical oncology notes documenting the patient s response to therapy showing no progression of disease. 2. Objective findings demonstrating no progression of disease (e.g., labs and imaging) when compared to previous studies. HCPCS J9041 Description Injection, bortezomib, 0.1 mg V. Important Reminder The purpose of this Medical Policy is to provide a guide to coverage. This Medical Policy is not intended to dictate to providers how to practice medicine. Nothing in this Medical Policy is intended to discourage or prohibit providing other medical advice or treatment deemed appropriate by the treating physician. Benefit determinations are subject to applicable member contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control.

4 Bortezomib (Velcade) 4 This Medical Policy has been developed through consideration of the medical necessity criteria under Hawaii s Patients Bill of Rights and Responsibilities Act (Hawaii Revised Statutes 432E-1.4), generally accepted standards of medical practice and review of medical literature and government approval status. HMSA has determined that services not covered under this Medical Policy will not be medically necessary under Hawaii law in most cases. If a treating physician disagrees with HMSA s determination as to medical necessity in a given case, the physician may request that HMSA reconsider the application of the medical necessity criteria to the case at issue in light of any supporting documentation. VI. References 1. DrugDex evaluations, Bortezomib clinical applications. Thomson Healthcare. Last modified: October 14, Millennium Pharmaceuticals, Inc. Velcade prescribing information. Cambridge, MA. Issued December NCCN Practice Guidelines in Oncology; Multiple Myeloma V NCCN Practice Guidelines in Oncology; Non- Hodgkin s Lymphomas V NCCN Drugs and Biologics Compendium; Bortezomib. 6. Richardson PG, Barlogie B, Berenson J, et al. A phase II study of bortezomib in relapsed, refractory myeloma. N Engl J Med. June 26, 2003; 348(26): The Medical Letter. July 21, 2003;45(1161): O'Connor OA R, Wright J, Moskowitz C, et al: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23(4): Lenz G, Dreyling M, Hiddemann W: Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol 2004; 83:71-77.

5 Bortezomib (Velcade) 5 Appendix Definition of Multiple Myeloma Smoldering (Asymptomatic) Myeloma Requires one or more of the following symptoms and no related organ or tissue impairment (no end organ damage, including bone lesions) or symptoms: A. M-protein in serum 1. IgG 3 g/dl, 2. IgA >1 g/dl, OR 3. Bence-Jones protein >1 g/24h B. Bone marrow clonal plasma cells 10% Active (Symptomatic) Myeloma Requires one or more of the symptoms of Smoldering (Asymptomatic) Myeloma in addition to one or more of the following symptoms: A. Calcium elevation (>11.5 mg/dl) [>2.65 mmol/l] B. Renal insufficiency (creatinine >2 mg/dl) [177 µmol/l or more] C. Anemia (hemoglobin <10 g/dl or 2 g/dl < normal) [<12.5 mmol/l < normal] D. Bone disease (lytic or osteopenic)

Velcade (bortezomib)

Velcade (bortezomib) Velcade (bortezomib) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 03/09/2004 Current Effective Date: 03/01/2018 POLICY A. INDICATIONS The indications below

More information

Velcade (bortezomib)

Velcade (bortezomib) Velcade (bortezomib) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 03/09/2004 Current Effective Date: 05/01/2017 POLICY A. INDICATIONS The indications below

More information

Gazyva (obinutuzumab)

Gazyva (obinutuzumab) Gazyva (obinutuzumab) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/201807/01/2018 POLICY A. INDICATIONS The indications

More information

Erythropoiesis Stimulating Agents (ESA)

Erythropoiesis Stimulating Agents (ESA) Erythropoiesis Stimulating Agents (ESA) Policy Number: Original Effective Date: MM.04.008 04/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription

More information

Perjeta (pertuzumab)

Perjeta (pertuzumab) Perjeta (pertuzumab) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/201809/16/2018 POLICY A. INDICATIONS The indications

More information

Torisel (temsirolimus)

Torisel (temsirolimus) Torisel (temsirolimus) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 10/01/2015 Current Effective Date: 11/1/2017 POLICY A. INDICATIONS The indications below

More information

Bevacizumab (Avastin)

Bevacizumab (Avastin) Bevacizumab (Avastin) Policy Number: Original Effective Date: MM.04.001 09/14/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2014 Section: Prescription Drugs Place(s) of Service:

More information

Torisel (temsirolimus)

Torisel (temsirolimus) Torisel (temsirolimus) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 11/01/2017TBD03/01/2017 POLICY A. INDICATIONS The indications

More information

Somatuline Depot (lanreotide)

Somatuline Depot (lanreotide) Somatuline Depot (lanreotide) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 12/01/2017TBD POLICY A. INDICATIONS The indications

More information

Clinical Policy: Pralatrexate (Folotyn) Reference Number: CP.PHAR.313 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Pralatrexate (Folotyn) Reference Number: CP.PHAR.313 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Folotyn) Reference Number: CP.PHAR.313 Effective Date: 02.01.17 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of

More information

Clinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: CP.PHAR.307 Effective Date: Last Review Date: 11.18

Clinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: CP.PHAR.307 Effective Date: Last Review Date: 11.18 Clinical Policy: (Bendeka, Treanda) Reference Number: CP.PHAR.307 Effective Date: 02.01.17 Last Review Date: 11.18 Coding Implications Revision Log Line of Business: Medicaid, HIM-Medical Benefit See Important

More information

Cyramza (ramucirumab)

Cyramza (ramucirumab) Cyramza (ramucirumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 03/01/2017TBD03/01/2018 POLICY A. INDICATIONS The indications

More information

Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage

Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: TBD003/01/201703/01/2018 POLICY A. INDICATIONS The indications

More information

Waldenstrom s Macroglobulinemia

Waldenstrom s Macroglobulinemia Waldenstrom s Macroglobulinemia : Introduction Waldenstrom s macroglobulinemia (WM) is a lymphoma, or cancer of the lymphatic system. It occurs in a type of white blood cell called a B-lymphocyte or B-cell,

More information

Velcade (bortezomib) Document Number: IC-0137

Velcade (bortezomib) Document Number: IC-0137 Velcade (bortezomib) Document Number: IC-0137 Last Review Date: 11/21/2017 Date of Origin: 11/28/2011 Dates Reviewed: 12/2011, 03/2012, 06/2012, 09/2012, 12/2012, 03/2013, 06/2013, 09/2013, 12/2013, 03/2014,

More information

Growth Hormone Therapy

Growth Hormone Therapy Growth Hormone Therapy Policy Number: Original Effective Date: MM.04.011 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/23/2014 Section: Prescription Drugs Place(s)

More information

Continuous Glucose Monitoring System

Continuous Glucose Monitoring System Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2017 Section: DME Place(s)

More information

Insulin Pumps - External

Insulin Pumps - External Insulin Pumps - External Policy Number: Original Effective Date: MM.01.004 04/01/2011 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/20174/1/2018 Section: DME Place(s) of

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1090-7 Program Prior Authorization/Notification Medication Revlimid (lenalidomide) P&T Approval Date 6/2009, 3/2010, 6/2010, 9/2010,

More information

Continuous Glucose Monitoring System

Continuous Glucose Monitoring System Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 4/1/2018 Section: DME Place(s)

More information

Continuous Glucose Monitoring System

Continuous Glucose Monitoring System Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2016 Section: DME Place(s)

More information

Subject: Bortezomib Injection

Subject: Bortezomib Injection 09-J0000-92 Original Effective Date: 04/15/09 Reviewed: 06/13/18 Revised: 01/01/19 Subject: Bortezomib Injection THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS,

More information

Refractory M ultiple Multiple M yeloma Myeloma

Refractory M ultiple Multiple M yeloma Myeloma Refractory Multiple Myeloma A Case Study Case: #1 48-Year-Old Male Presented to the ER with Fatigue and Acute Severe Lower Back Pain Patient assessment: X-ray of lumbar spine: L4 compression fracture,

More information

Low-Molecular-Weight Heparin

Low-Molecular-Weight Heparin Low-Molecular-Weight Heparin Policy Number: Original Effective Date: MM.04.019 10/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO 10/28/2011 Section: Prescription Drugs Place(s) of Service:

More information

Keytruda (pembrolizumab)

Keytruda (pembrolizumab) Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The

More information

Home Total Parenteral Nutrition for Adults

Home Total Parenteral Nutrition for Adults Home Total Parenteral Nutrition for Adults Policy Number: Original Effective Date: MM.08.007 05/21/1999 Line(s) of Business: Current Effective Date: PPO, HMO, QUEST Integration 05/27/2016 Section: Home

More information

Forms Revision: Myeloma Changes

Forms Revision: Myeloma Changes Sharing knowledge. Sharing hope. Forms Revision: Myeloma Changes J. Brunner, PA-C and A. Dispenzieri, MD February 2013 Disclosures Janet Brunner, PA-C I have no relevant conflicts of interest to disclose.

More information

Pulmonary Hypertension Drugs

Pulmonary Hypertension Drugs Pulmonary Hypertension Drugs Policy Number: Original Effective Date: MM.04.028 10/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/22/2015 Section: Prescription Drugs

More information

Negative Pressure Wound Therapy (NPWT)

Negative Pressure Wound Therapy (NPWT) Negative Pressure Wound Therapy (NPWT) Policy Number: Original Effective Date: MM.01.005 11/19/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 01/01/2015 Section: DME Place(s) of Service:

More information

Lung-Volume Reduction Surgery ARCHIVED

Lung-Volume Reduction Surgery ARCHIVED Lung-Volume Reduction Surgery ARCHIVED Policy Number: Original Effective Date: MM.06.008 04/15/2005 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST 03/22/2013 Section: Surgery Place(s) of

More information

2016: Plasma Cell Disorders Pre-HCT Data

2016: Plasma Cell Disorders Pre-HCT Data 2016: Plasma Cell Disorders Pre-HCT Data Registry Use Only Sequence Number: Date Received: Key Fields CIBMTR Center Number: Date of HCT for which this form is being completed: / / YYYY MM DD HCT type (check

More information

Managing Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient. Case Study

Managing Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient. Case Study Managing Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient Case Study 2 2011 Newly Diagnosed Patient The patient is a 61-year-old Caucasian female History of high blood pressure

More information

Intensity Modulated Radiation Therapy (IMRT)

Intensity Modulated Radiation Therapy (IMRT) Intensity Modulated Radiation Therapy (IMRT) Policy Number: Original Effective Date: MM.05.006 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO 06/24/2011 Section: Radiology Place(s) of

More information

Management Update: Multiple Myeloma. Presented by Prof. Dr. Khan Abul Kalam Azad Professor of Medicine Dhaka Medical College

Management Update: Multiple Myeloma. Presented by Prof. Dr. Khan Abul Kalam Azad Professor of Medicine Dhaka Medical College Management Update: Multiple Myeloma Presented by Prof. Dr. Khan Abul Kalam Azad Professor of Medicine Dhaka Medical College Introduction Multiple myeloma - clonal plasma cell neoplasm Monoclonal antibody

More information

Major Diagnostic Criteria

Major Diagnostic Criteria Multiple Myeloma Elizabeth Ann Coleman, PhD, RNP, AOCN Professor and Chair, Dept. of Nursing Science Cooper Chair in Oncology Nursing, College of Nursing Professor, Dept. of Internal Medicine, College

More information

Plasma Cell Disorders (PCD) Pre-HCT Data

Plasma Cell Disorders (PCD) Pre-HCT Data Plasma Cell Disorders (PCD) Pre-HCT Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: CIBMTR Recipient ID: Date of HCT for which this form is being completed: HCT type: (check

More information

Dupixent (dupilumab)

Dupixent (dupilumab) Dupixent (dupilumab) Line(s) of Business: HMO; PPO; QUEST Integration Effective Date: TBD POLICY A. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered

More information

Treatment of Relapsed. A Case Study

Treatment of Relapsed. A Case Study Treatment of Relapsed Multiple Myeloma A Case Study Case Presentation Mr. V is a 61-year-old man previously diagnosed with ISS stage III IgG λ multiple myeloma with bone lesions, normal FISH and cytogenetics,

More information

Clinical Policy: Brentuximab Vedotin (Adcetris) Reference Number: CP.PHAR.303

Clinical Policy: Brentuximab Vedotin (Adcetris) Reference Number: CP.PHAR.303 Clinical Policy: (Adcetris) Reference Number: CP.PHAR.303 Effective Date: 02/17 Last Review Date: 02/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Venclexta) Reference Number: CP.PHAR.129 Effective Date: 07.17.18 Last Review Date: 11.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this

More information

Management of Multiple Myeloma

Management of Multiple Myeloma Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.

More information

Bariatric Surgery MM /11/2001. HMO; PPO; QUEST 05/01/2012 Section: Surgery Place(s) of Service: Outpatient; Inpatient

Bariatric Surgery MM /11/2001. HMO; PPO; QUEST 05/01/2012 Section: Surgery Place(s) of Service: Outpatient; Inpatient Bariatric Surgery Policy Number: Original Effective Date: MM.06.003 09/11/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 05/01/2012 Section: Surgery Place(s) of Service: Outpatient;

More information

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2017

More information

Applied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder

Applied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder Applied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder Policy Number: Original Effective Date: MM.12.022 01/01/2016 Line(s) of Business: Current Effective Date: HMO; PPO; Fed 87; FEP;

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_ transplantation_for_primary_amyloidosis 2/2001 11/2018 11/2019 11/2018 Description

More information

Management of Multiple Myeloma: The Changing Paradigm

Management of Multiple Myeloma: The Changing Paradigm Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old

More information

Clinical Policy: Obinutuzumab (Gazyva) Reference Number: CP.PHAR.305 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Obinutuzumab (Gazyva) Reference Number: CP.PHAR.305 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Gazyva) Reference Number: CP.PHAR.305 Effective Date: 02.01.17 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of

More information

GROWTH HORMONE THERAPY

GROWTH HORMONE THERAPY GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 12/30/201601/01/2018TBD03/01/2018 POLICY A. INDICATIONS The indications

More information

GROWTH HORMONE THERAPY

GROWTH HORMONE THERAPY GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 03/01/201804/01/2019 POLICY A. INDICATIONS The indications below including

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Istodax) Reference Number: CP.PHAR.314 Effective Date: 01.01.17 Last Review Date: 11.18 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Yescarta) Reference Number: CP.PHAR.XX Effective Date: 10.31.17 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Gazyva) Reference Number: CP.PHAR.305 Effective Date: 02.01.17 Last Review Date: 11.18 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important Reminder

More information

Oxygen and Oxygen Equipment

Oxygen and Oxygen Equipment Oxygen and Oxygen Equipment Policy Number: Original Effective Date: MM.01.008 12/01/2010 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 08/25/2017 Section: DME Place(s) of Service:

More information

Oxygen and Oxygen Equipment

Oxygen and Oxygen Equipment Oxygen and Oxygen Equipment Policy Number: Original Effective Date: MM.01.008 12/01/2010 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 09/01/2013 Section: DME Place(s) of Service: Home I.

More information

TRANSPARENCY COMMITTEE OPINION. 27 January 2010

TRANSPARENCY COMMITTEE OPINION. 27 January 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 January 2010 TORISEL 25 mg/ml, concentrate for solution and diluent for solution for infusion Box containing 1

More information

Applied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder

Applied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder Applied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder Policy Number: Original Effective Date: MM.12.022 01/01/2016 Line(s) of Business: Current Effective Date: HMO; PPO; Fed 87; FEP;

More information

Treatment of Waldenström s Macroglobulinemia Mayo Consensus

Treatment of Waldenström s Macroglobulinemia Mayo Consensus Treatment of Waldenström s Macroglobulinemia Mayo Consensus Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive Cancer Center Mayo Clinic

More information

Micro-Invasive Glaucoma Surgery (Aqueous Stents)

Micro-Invasive Glaucoma Surgery (Aqueous Stents) Micro-Invasive Glaucoma Surgery (Aqueous Stents) Policy Number: Original Effective Date: MM.06.029 02/01/2019 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 02/01/2019 Section:

More information

GROWTH HORMONE THERAPY

GROWTH HORMONE THERAPY GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below including FDA-approved

More information

Intracellular Micronutrient Analysis

Intracellular Micronutrient Analysis Intracellular Micronutrient Analysis Policy Number: Original Effective Date: MM.02.019 11/01/2013 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 08/22/2014 Section: Medicine Place(s)

More information

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2013 Section:

More information

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 11/20/2015

More information

Intracellular Micronutrient Analysis

Intracellular Micronutrient Analysis Intracellular Micronutrient Analysis Policy Number: Original Effective Date: MM.02.019 11/01/2013 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 08/28/2015 Section: Medicine Place(s)

More information

Remicade (Infliximab)

Remicade (Infliximab) Remicade (Infliximab) Policy Number: Original Effective Date: MM.04.016 11/18/2003 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 07/26/2013 Section: Prescription Drugs Place(s)

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Imbruvica) Reference Number: HIM.PA.SP48 Effective Date: 01.01.18 Last Review Date: Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this

More information

Revlimid. Revlimid (lenalidomide) Description. Section: Prescription Drugs Effective Date: October 1, 2016

Revlimid. Revlimid (lenalidomide) Description. Section: Prescription Drugs Effective Date: October 1, 2016 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.47 Subject: Revlimid Page: 1 of 7 Last Review Date: September 15, 2016 Revlimid Description Revlimid

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.HNMC.27 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.HNMC.27 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC Clinical Policy: (Opdivo) Reference Number: CP.HNMC.27 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy for

More information

Intensity Modulated Radiation Therapy (IMRT)

Intensity Modulated Radiation Therapy (IMRT) Intensity Modulated Radiation Therapy (IMRT) Policy Number: Original Effective Date: MM.05.006 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 03/01/2015 Section: Radiology

More information

Clinical Policy: Idelalisib (Zydelig) Reference Number: CP.CPA.278 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Idelalisib (Zydelig) Reference Number: CP.CPA.278 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: (Zydelig) Reference Number: CP.CPA.278 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important

More information

Posterior Tibial Nerve Stimulation

Posterior Tibial Nerve Stimulation Posterior Tibial Nerve Stimulation Policy Number: Original Effective Date: MM.02.025 01/01/2015 Lines of Business: Current Effective Date: HMO; PPO; QUEST Integration 02/01/2015 Section: Medicine Place(s)

More information

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2015

More information

Polysomnography and Sleep Studies

Polysomnography and Sleep Studies Polysomnography and Sleep Studies Policy Number: Original Effective Date: MM.02.016 09/14/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/01/2014 Section: Medicine Place(s)

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Venclexta) Reference Number: CP.PHAR.129 Effective Date: 07.17.18 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Tisagenlecleucel (Kymriah) Reference Number: CP.PHAR.361 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at

More information

Positive Airway Pressure and Oral Devices for the Treatment of Obstructive Sleep Apnea

Positive Airway Pressure and Oral Devices for the Treatment of Obstructive Sleep Apnea Positive Airway Pressure and Oral Devices for the Treatment of Obstructive Sleep Apnea Policy Number: Original Effective Date: MM.01.009 11/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_waldenstrom_macroglobulinemia

More information

Revlimid. Revlimid (lenalidomide) Description. Section: Prescription Drugs Effective Date: July 1, 2015

Revlimid. Revlimid (lenalidomide) Description. Section: Prescription Drugs Effective Date: July 1, 2015 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.47 Subject: Revlimid Page: 1 of 6 Last Review Date: June 19, 2015 Revlimid Description Revlimid (lenalidomide)

More information

Physical Therapy MM /15/2003

Physical Therapy MM /15/2003 Physical Therapy Policy Number: Original Effective Date: MM.09.005 07/15/2003 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/23/2017 Line(s) of Business Excluded: Federal Employee

More information

Waldenstrom s Macroglobulinemia

Waldenstrom s Macroglobulinemia Waldenstrom s Macroglobulinemia : Monoclonal Antibodies Introduction Waldenstrom s macroglobulinemia (WM) is a lymphoma, or cancer of the lymphatic system. It occurs in a type of white blood cell called

More information

Subject: Belinostat (Beleodaq ) Injection

Subject: Belinostat (Beleodaq ) Injection 09-J2000-21 Original Effective Date: 11/15/14 Reviewed: 01/09/19 Revised: 02/15/19 Subject: Belinostat (Beleodaq ) Injection THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION

More information

Management of Multiple Myeloma: The Changing Paradigm

Management of Multiple Myeloma: The Changing Paradigm Management of Multiple Myeloma: The Changing Paradigm Frontline Therapy for Newly Diagnosed Patients Saad Usmani, MD FACP Levine Cancer Institute Introduction: Case Presentation 64-year-old woman with

More information

Photochemotherapy MM /09/2004. HMO; PPO; QUEST Integration June 1, 2016 Section: Medicine Place(s) of Service: Home; Office

Photochemotherapy MM /09/2004. HMO; PPO; QUEST Integration June 1, 2016 Section: Medicine Place(s) of Service: Home; Office Photochemotherapy Policy Number: Original Effective Date: MM.02.015 11/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration June 1, 2016 Section: Medicine Place(s) of Service:

More information

Prophylactic Mastectomy

Prophylactic Mastectomy Prophylactic Mastectomy Policy Number: Original Effective Date: MM.06.010 01/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO 07/22/2011 Section: Surgery Place(s) of Service: Inpatient I.

More information

CLINICAL MEDICATION POLICY

CLINICAL MEDICATION POLICY Policy Name: Policy Number: Approved By: CLINICAL MEDICATION POLICY Adcetris (Brentuximab Vedotin) MP-035-MD-WV Provider Notice Date: 07/03/2017 Original Effective Date: 08/03/2017 Annual Approval Date:

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Kymriah) Reference Number: CP.PHAR.361 Effective Date: 09.26.17 Last Review Date: 11.18 Line of Business: Commercial, Medicaid, HIM-Medical Benefit Revision Log See Important Reminder

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY Policy Name: Policy Number: Approved By: CLINICAL MEDICAL POLICY ADCETRIS (Brentuximab Vedotin) MP-035-MD-DE Provider Notice Date: 11/1/2016 Original Effective Date: 12/1/2016 Medical Management Annual

More information

Positive Airway Pressure and Oral Devices for the Treatment of Obstructive Sleep Apnea

Positive Airway Pressure and Oral Devices for the Treatment of Obstructive Sleep Apnea Positive Airway Pressure and Oral Devices for the Treatment of Obstructive Sleep Apnea Policy Number: Original Effective Date: MM.01.009 11/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO;

More information

UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma

UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Supported by a grant from Supported by a grant from UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Jonathan W.

More information

DIAGNOSIS AND TREATMENT OF WALDENSTRÖM S MACROGLOBULINAEMIA IN THE NETHERLANDS. Monique Minnema UMC Utrecht

DIAGNOSIS AND TREATMENT OF WALDENSTRÖM S MACROGLOBULINAEMIA IN THE NETHERLANDS. Monique Minnema UMC Utrecht DIAGNOSIS AND TREATMENT OF WALDENSTRÖM S MACROGLOBULINAEMIA IN THE NETHERLANDS Monique Minnema UMC Utrecht Organisation of hematological care in the Netherlands Intensive chemotherapy, including acute

More information

M-Protien, what to do next? Ismail A Sharif MD, FRCPc Internal Medicine Day 22 nd April 2016

M-Protien, what to do next? Ismail A Sharif MD, FRCPc Internal Medicine Day 22 nd April 2016 + M-Protien, what to do next? Ismail A Sharif MD, FRCPc Internal Medicine Day 22 nd April 2016 + Disclosures Advisory Boards: AMGEN, Lundbeck, NOVARTIS + Subtypes of Plasma Cell Disorders Increased Plasma

More information

Extracorporeal Membrane Oxygenation (ECMO)

Extracorporeal Membrane Oxygenation (ECMO) Extracorporeal Membrane Oxygenation (ECMO) Policy Number: Original Effective Date: MM.12.006 05/16/2006 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 11/01/2014 Section: Other/Miscellaneous

More information

Xolair (omalizumab) Limitation of Use: Xolair is not indicated for treatment of other forms of urticaria.

Xolair (omalizumab) Limitation of Use: Xolair is not indicated for treatment of other forms of urticaria. Xolair (omalizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 11/18/2003 Current Effective Date: 12/01/2017TBD POLICY A. INDICATIONS The indications below

More information

Incontinence Supplies

Incontinence Supplies Incontinence Supplies Policy Number: Original Effective Date: MM.12.020 07/01/2015 Lines of Business: Current Effective Date: QUEST Integration 09/28/2018 Section: Other/Miscellaneous Place(s) of Service:

More information

Poteligeo (mogamulizmuab-kpkc)

Poteligeo (mogamulizmuab-kpkc) Poteligeo (mogamulizmuab-kpkc) Policy Number: 5.02.556 Last Review: 1/2019 Origination: 1/2019 Next Review: 1/2020 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Poteligeo

More information

Panel Discussion/References

Panel Discussion/References Follicular Lymphoma (FOLL) Panel discussion to reassess the category designation for lenalidomide + rituximab as a firstline therapy for FL. Panel discussion to reassess the inclusion of radioimmunotherapy

More information

Myeloma care and proteasome inhibitors. Brendan M. Weiss, MD Abramson Cancer Center University of Pennsylvania

Myeloma care and proteasome inhibitors. Brendan M. Weiss, MD Abramson Cancer Center University of Pennsylvania Myeloma care and proteasome inhibitors Brendan M. Weiss, MD Abramson Cancer Center University of Pennsylvania Why care about CV toxicities in MM? Median age 72 years About 2/3 have CV disease at baseline

More information